Penn FTD Center

As amyloid-targeting therapies become part of Alzheimer’s care, researchers are working to better understand who is most likely to benefit and who may face greater risk.

At , Christopher Brown, MD, PhD, will present research using plasma proteomics to study response to amyloid-targeting therapy.

His work looks at protein changes during treatment that may help predict cognitive benefit or higher risk of side effects.

FTD Fact Friday: Two rare neurological movement disorders associated with FTD, corticobasal syndrome and progressive supranuclear palsy, occur when the parts of the brain that control movement are damaged.

📍 Check out our Support & Resources tab for helpful tools and links.
📰 Read our monthly blog in the Latest News tab.
🔎 Interested in Observational Research or Clinical Trials? Click the links to learn more about the participation in studies.

Find more information on the Penn FTD Center website!

The objective of observational research is to observe participants naturally, without any interventions or treatments. Penn FTD Center Senior Clinical Research Coordinator Ashlyn O'Halloran writes about observational research in our blog post!

Read now on our website!

🎉 Congrats to the Penn FTD Center's Genetic Counselor Laynie Dratch on her recent award as an Outstanding Supervisor with the Genetic Counselor Educators Association (GCEA)!

Thank you for all your hard work, Laynie!